Literature DB >> 6577950

Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.

W E Berdel, M Fromm, U Fink, W Pahlke, U Bicker, A Reichert, J Rastetter.   

Abstract

Thioether-lysophospholipids inhibited the in vitro incorporation of [3H]thymidine into blasts of 8 leukemias, lymphocytes of 3 chronic lymphocytic leukemias, and cells of 12 different solid tumors of human origin. This effect correlated with trypan blue dye exclusion, which was used to assess cell damage. Scanning electron microscopy revealed severe membrane destruction after incubation with thioether-lysophospholipids. Cytostatic and cytotoxic effects of thioether-lysophospholipids were dependent on dosage and incubation time. Destruction of leukemic blasts was completed with greater than or equal to 5 micrograms/ml after an incubation of greater than or equal to 48 hr, but 10 to 20 micrograms/ml were necessary in solid tumors. Ester-linked 2-lysophosphatidylcholine was ineffective in the same dose range, which points to the requirement of the alkyl moiety in SN1 of the molecule for the antineoplastic properties of lysophospholipid analogues.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6577950

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.

Authors:  M Shoji; R L Raynor; E A Fleer; H Eibl; W R Vogler; J F Kuo
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

2.  Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Authors:  A W Himmelmann; S Danhauser-Riedl; G Steinhauser; R Busch; E J Modest; A Noseda; J Rastetter; W R Vogler; W E Berdel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation.

Authors:  W R Vogler; A C Olson; S Okamoto; L B Somberg; L Glasser
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

4.  Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients.

Authors:  D B Herrmann; H A Neumann; W E Berdel; M E Heim; M Fromm; D Boerner; U Bicker
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

5.  The chemotherapeutic potential of glycol alkyl ethers: structure-activity studies of nine compounds in a Fischer-rat leukemia transplant model.

Authors:  M P Dieter; C W Jameson; R R Maronpot; R Langenbach; A G Braun
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of optical isomers of ether and thioether lipids.

Authors:  C I Hong; S H An; A Nechaev; A J Kirisits; R Vig; C R West
Journal:  Lipids       Date:  1993-11       Impact factor: 1.880

7.  Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.

Authors:  M E Heim; M Swoboda; W Pahlke; L Edler; U Bicker
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

8.  Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells.

Authors:  R Girgert; P Schweizer; I Bock; R Narr; G Bruchelt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Effect of cell density on cytotoxicity of ether lipid analogues in variants of B16 murine melanoma.

Authors:  L L Trulla; A Magistrelli; M Salmona; M T Tacconi
Journal:  Lipids       Date:  1993-05       Impact factor: 1.880

10.  Synthesis of thioether phosphocholine analogues.

Authors:  E Bosies; D B Herrmann; U Bicker; R Gall; W Pahlke
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.